Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

ABL Bio Financials and Metrics

Summary Metrics

Founding Date


ABL Bio total Funding

$90.8 m

ABL Bio latest funding size

$65 m

Time since last funding

4 years ago

ABL Bio investors

ABL Bio's latest funding round in June 2018 was reported to be $65 m. In total, ABL Bio has raised $90.8 m
Show all financial metrics

ABL Bio Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

ABL Bio Online and Social Media Presence

Embed Graph

ABL Bio News and Updates

Insights on the Antibody Drug Conjugates Global Market to 2030 - Featuring 6 Dimensions Capital, AbbVie and ABL Bio Among Others

Dublin, Oct. 08, 2021 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market by Indication, Linker, Payload, Target Antigens and Geography: Industry Trends and Global Forecasts, 2021-2030" report has been added to's offering.

ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody

South Korea's MFDS clears IND application for a Phase 1 study evaluating the safety and preliminary efficacy of ABL501 as a monotherapy for solid tumor treatment ABL's third IND this year for bispecific antibody therapeutics SEONGNAM, South Korea, Aug. 4, 2021 /PRNewswire/ -- ABL Bio, Inc....

ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody

ABL503/TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monotherapy as well as a good safety profile ABL503 currently in Phase 1 trial to evaluate the safety, tolerability, MTD PK and PD in patients with advanced or metastatic solid tumors SEONGNAM, South...

I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors

SHANGHAI, China and GAITHERSBURG, Md., March 30, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the development of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter “ABL”), a South Korean biotech specializing in bis…

ABL Bio Frequently Asked Questions

  • When was ABL Bio founded?

    ABL Bio was founded in 2016.

  • How many employees does ABL Bio have?

    ABL Bio has 33 employees.

  • Who are ABL Bio competitors?

    Competitors of ABL Bio include Courier Therapeutics, ImmVira and Precision Medicines.